Emerging in the arena of obesity management, retatrutide presents a distinct strategy. Unlike many current medications, retatrutide functions as a dual agonist, at once engaging both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) binding sites. This dual stimulation promotes various helpful effects, including